Jujuboside A

Research use only, not for human use.

Jujuboside A is a glycoside extracted from Semen Ziziphi Spinosae, having neurophysiological inhibitory effects, used as a potential therapeutic agent for the treatment of Alzheimer?s disease.

Jujuboside A (JuA) is a saponin isolated from Semen Ziziphus spinosa (SZS) used in Traditional Chinese Medicine.

Jujuboside A at the low dose of 41 μM (about 0.05 g/L) induces significant increase of GABA(A) receptor α1, α5, β2 subunit mRNAs in both 24 and 72h treatments. Jujuboside A at the high dose of 82 μM (about 0.1 g/L) significantly increases GABA(A) receptor α1, α5 subunit mRNA levels and decreases β2 subunit mRNA level at 24h treatment, and decreases GABA(A) receptor subunit α1, β2 mRNAs expression at 72h treatment. Jujuboside A pretreatment could reverse the reduction of cell viability and better the injury of H9C2 cells induced by ISO. Jujuboside A could accelerate the phosphorylation of PI3K, Akt, and mTOR. Jujuboside A could significantly decrease the ratio of microtubule-associated protein LC3-II/I in H9C2 cells.

During daytime (9:00-15:00), jujubosides significantly increases the total sleep and rapid eye movement (REM) sleep without significant influence on non-REM (NREM) sleep. During nighttime (21:00-3:00), jujubosides significantly increases the total sleep and NREM sleep especially the light sleep while shows no significant effect on REM sleep and slow wave sleep (SWS). Intracerebroventricular treatment with Jujuboside A significantly mitigates learning and memory impairment in mice induced by Aβ1–42 as measured by the Y-maze, active avoidance and Morris water maze. Intracerebroventricular treatment with Jujuboside A reduces the level of Aβ1–42 in hippocampus, significantly inhibits the activities of acetylcholinesterase (AChE) and NO, and decreases the amount of the increased malondialdehyde (MDA) in the hippocampus and cerebral cortex of mice treated with intracerebroventricular injection of Aβ1–42.

Jujuboside A

Cytoskeleton/Cell Adhesion Molecules

Glucokinase

GLU

Others-Field

——

55466-04-1

1207.36

C58H94O26

>98% (HPLC)

H2O : 50 mg/mL 41.41 mM;

[C@@H]1([C@@H]([C@@H]([C@H]([C@@H](O1)C)O)O)O)O[C@H]1[C@@H](OC[C@@H]([C@@H]1O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)O)O)O[C@H]1[C@@H]([C@H]([C@@H](CO1)O)O)O)O)O[C@@H]1C([C@@H]2CC[C@@]3([C@H](CC[C@@H]4[C@@H]5[C@@]6(OC[C@]34C6)O[C@H](C[C@]5(C)O)C=C(C)C)[C@]2(CC1)C)C)(C)C

(2S,3R,4R,5R,6S)-2-(((2R,3R,4S,5S)-4-(((2S,3R,4S,5S,6R)-4,5-dihydroxy-6-((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)methyl)-3-(((2S,3R,4S,5R)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-5-hydroxy-2-(((1S,3R,4aS,6aR,6bR,8aR,10S,12aR,12bR,14aR,14bS)-1-hydroxy-1,6b,9,9,12a-pentamethyl-3-(2-methylprop-1-en-1-yl)hexadecahydro-1H,6H-4a,6a-methanonaphtho[1,2-h]pyrano[2,3-c]isochromen-10-yl)oxy)tetrahydro-2H-pyran-3-yl)oxy)-6-methyltetrahydro-2H-pyran-3,4,5-triol

(-20℃)

With Ice Pack

≥ 2 years